Fimea's finances 2021

Fimea is a net budgeted agency that is funded mainly by the customer fees of pharmaceutical operators. In 2021, marketing authorisations for medicinal products, licence and audit fees for pharmaceutical operators and quality control fees under the separate statute account for approximately 82% of the agency's total funding. The remaining 18% is funded by the state budget, and it includes the general steering of pharmacovigilance by the authorities, the operation of the pharmacopoeia and the assessment of pharmacotherapies process. Fimea was granted EUR 5,373,000 in the 2021 budget.

In 2021, the revenue from Fimea's chargeable activities was approximately EUR 27.1 million and the operating costs EUR 25.2 million. In 2021, the revenue from chargeable activities managed to cover the costs arising from the activities as in the previous year. This is also reflected in the economic efficiency index describing total productivity, which means a change of 102.3 over two consecutive years.

In 2021, 82% of the funding for Fimea's operations was received from pharmaceutical operators. Approximately 91% of the revenue from chargeable activities consists of performances under public law, such as revenues from marketing authorisations for medicinal products, licence and audit fees for pharmaceutical operators, and about 9% from quality control fees under the separate statute. In accordance with the Act on Criteria for Charges Payable to the State, Fimea must price the performances under public law so that they correspond to the costs of their production. In 2021, the cost correlation of Fimea's chargeable operations was 108%.